1,000 women in England are said to benefit from the Endometriosis pill, as the NHS approve its use.
Endometriosis is the result of cells, similar to those in the womb lining (uterus), growing in other parts of the body.
Symptoms caused by this include:
Severe period pain that prevents the ability of doing normal activities
Heavy periods
Extreme tiredness (fatigue)
Difficulty getting pregnant
Pain during or after sex
The organisation Endometriosis UK has welcomed the approval of the pill, with hopes that the medication is accepted for the whole of the UK.
Endometriosis affects 1 in 10 women in the UK. 16.7 million sick days annually are taken due to symptoms linked to periods.
However, the pill is said to only be able to help a small number of people:
Also known as relugolix combination therapy, it is a type of ‘medical menopause’ combined with HRT, and we note that it may be suitable for only a small proportion of the 1.5 million with the disease.”
Endometriosis UK
Submitted Article
Headline
Short Headline
Standfirst
Published Article
HeadlineThe NHS have approved the first daily pill for Endometriosis
Short Headline England's first endometriosis daily pill to be rolled out on the NHS
StandfirstThe pill is the first at home treatment to be offered where surgery isn't effective
1,000 women in England are said to benefit from the Endometriosis pill, as the NHS approve its use.
Endometriosis is the result of cells, similar to those in the womb lining (uterus), growing in other parts of the body.
Symptoms caused by this include:
Severe period pain that prevents the ability of doing normal activities
Heavy periods
Extreme tiredness (fatigue)
Difficulty getting pregnant
Pain during or after sex
The organisation Endometriosis UK has welcomed the approval of the pill, with hopes that the medication is accepted for the whole of the UK.
Endometriosis affects 1 in 10 women in the UK. 16.7 million sick days annually are taken due to symptoms linked to periods.
However, the pill is said to only be able to help a small number of people:
Also known as relugolix combination therapy, it is a type of ‘medical menopause’ combined with HRT, and we note that it may be suitable for only a small proportion of the 1.5 million with the disease.”
